72.35
price down icon0.89%   -0.65
pre-market  Vorhandelsmarkt:  72.49   0.14   +0.19%
loading
Schlusskurs vom Vortag:
$73.00
Offen:
$72.89
24-Stunden-Volumen:
3.97M
Relative Volume:
0.75
Marktkapitalisierung:
$112.19B
Einnahmen:
$54.98B
Nettoeinkommen (Verlust:
$7.77B
KGV:
29.06
EPS:
2.49
Netto-Cashflow:
$9.14B
1W Leistung:
+2.09%
1M Leistung:
+0.36%
6M Leistung:
+7.14%
1J Leistung:
-9.92%
1-Tages-Spanne:
Value
$72.18
$72.93
1-Wochen-Bereich:
Value
$70.60
$73.39
52-Wochen-Spanne:
Value
$61.24
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
Firmenname
Astrazeneca PLC
Name
Telefon
44 20 3749 5000
Name
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Mitarbeiter
61,100
Name
Twitter
@AstraZeneca
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
AZN's Discussions on Twitter

Vergleichen Sie AZN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
72.35 219.73B 54.98B 7.77B 9.14B 2.49

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-15 Eingeleitet Exane BNP Paribas Outperform
2025-02-13 Hochstufung UBS Neutral → Buy
2025-02-12 Eingeleitet Morgan Stanley Overweight
2024-11-20 Hochstufung UBS Sell → Neutral
2024-11-06 Hochstufung Deutsche Bank Sell → Hold
2024-09-13 Herabstufung Deutsche Bank Hold → Sell
2024-05-30 Eingeleitet Goldman Buy
2024-04-16 Hochstufung Deutsche Bank Sell → Hold
2024-02-08 Herabstufung Deutsche Bank Hold → Sell
2024-01-23 Eingeleitet Morgan Stanley Overweight
2024-01-16 Fortgesetzt UBS Sell
2024-01-03 Herabstufung Jefferies Buy → Hold
2023-12-18 Eingeleitet HSBC Securities Buy
2023-09-25 Hochstufung Jefferies Hold → Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-07-12 Hochstufung UBS Neutral → Buy
2023-07-05 Herabstufung Deutsche Bank Buy → Hold
2023-04-11 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-01-05 Eingeleitet BMO Capital Markets Outperform
2022-09-15 Herabstufung Credit Suisse Outperform → Neutral
2022-09-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-08-29 Hochstufung Argus Hold → Buy
2022-06-14 Herabstufung UBS Buy → Neutral
2022-02-11 Hochstufung DZ Bank Sell → Hold
2021-12-07 Herabstufung Jefferies Buy → Hold
2021-08-12 Fortgesetzt JP Morgan Overweight
2021-04-12 Herabstufung Argus Buy → Hold
2021-03-16 Hochstufung Jefferies Hold → Buy
2021-02-25 Hochstufung UBS Neutral → Buy
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-12-07 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-11-30 Hochstufung UBS Sell → Neutral
2020-11-11 Hochstufung HSBC Securities Reduce → Hold
2020-09-29 Eingeleitet Berenberg Buy
2019-11-22 Eingeleitet SVB Leerink Outperform
2019-10-25 Hochstufung Liberum Hold → Buy
2019-04-02 Herabstufung UBS Neutral → Sell
2019-02-05 Eingeleitet Exane BNP Paribas Outperform
2019-01-25 Hochstufung Shore Capital Hold → Buy
2018-12-11 Fortgesetzt Jefferies Hold
2018-10-09 Eingeleitet Guggenheim Buy
2018-08-16 Herabstufung Jefferies Buy → Hold
2018-03-19 Hochstufung Jefferies Hold → Buy
2018-02-06 Bestätigt Leerink Partners Mkt Perform
2018-02-05 Bestätigt Bernstein Outperform
2018-01-18 Bestätigt Leerink Partners Mkt Perform
2017-12-29 Hochstufung JP Morgan Neutral → Overweight
2017-10-16 Hochstufung Credit Suisse Neutral → Outperform
2017-09-25 Hochstufung Exane BNP Paribas Neutral → Outperform
2017-09-22 Hochstufung Bernstein Mkt Perform → Outperform
Alle ansehen

Astrazeneca PLC Aktie (AZN) Neueste Nachrichten

pulisher
Jun 04, 2025

AstraZeneca (AZN) Veteran Joins Perrigo Leadership Team | AZN St - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Hydrogel-based Drug Delivery System Market Top Companies Study - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Transcript : AstraZeneca PLC Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

AZN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment - Yahoo

Jun 03, 2025
pulisher
Jun 03, 2025

M42 Partners with AstraZeneca, Sophia Genetics for Liquid Biopsy Testing in UAE - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

AstraZeneca: Enhertu promising against breast cancer - marketscreener.com

Jun 03, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Reports Promising Phase 3 Results for Enhertu and Perjeta Combo - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer (AZN:NASDAQ) - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Considered for Potential Pharma Collaborations | AZN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

astrazeneca announces total voting rights update for may 2025 By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

astrazeneca reports block listing interim review for share schemes - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

astrazeneca reports block listing interim review for share schemes By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Highlights Encouraging Enhertu Results in Breast Cancer Trial | AZN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study - Bloomberg

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Highlights Success in Breast Cancer Trial with Camizestrant | AZN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca: camizestrant effective in breast cancer - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Astra Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca - Britannica

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit

Jun 02, 2025
pulisher
Jun 01, 2025

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6 - insights.citeline.com

Jun 01, 2025
pulisher
Jun 01, 2025

PRESS DIGEST- Financial TimesJune 2 - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boo - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times

Jun 01, 2025
pulisher
Jun 01, 2025

Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive

Jun 01, 2025
pulisher
Jun 01, 2025

IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com

Jun 01, 2025
pulisher
May 30, 2025

AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News

May 30, 2025
pulisher
May 30, 2025

AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters

May 30, 2025
pulisher
May 30, 2025

Danaher Partners With AstraZeneca to Support Precision Medicine - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues

May 30, 2025
pulisher
May 30, 2025

Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance

May 30, 2025
pulisher
May 29, 2025

AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360

May 29, 2025
pulisher
May 29, 2025

Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 28, 2025

Responsible care and use of animals in research - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance

May 28, 2025

Finanzdaten der Astrazeneca PLC-Aktie (AZN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
Kapitalisierung:     |  Volumen (24h):